Health-related quality of life in children with chronic immune thrombocytopenia in China

Table 3 Comparison between scores of child/proxy and parent self-reports in relation to clinical characteristics and treatment of ITP

Clinical Characteristics and Treatment of ITP		KIT				KIT				KIT				PedsQL™				PedsQL™
		Child self-report				Parent proxy report				Parent impact report				Child self-report				Parent proxy report
		N	Mean	SD	P ^a	N	Mean	SD	P ^a	N	Mean	SD	P ^a	N	Mean	SD	P ^a	N	Mean	SD	P ^a
Gender	Male	19	79.29	12.39	0.64	29	72.48	18.92	0.66	29	42.40	17.57	0.29	18	85.40	14.30	0.70	28	85.69	14.25	0.83
Gender	Female	5	76.02	13.48		13	75.46	22.78		13	35.92	17.75		4	84.37	12.22		12	82.61	15.37
Platelet count	≤30	8	69.80	14.57	0.01	16	63.45	21.05	0.01	16	34.99	19.35	0.11	8	78.57	14.44	0.14	17	75.44	14.45	0.00
Platelet count	>30	16	83.01	8.63		26	80.17	16.35		26	44.06	15.78		14	88.19	13.36		23	91.53	8.23
BM	Never	3	82.51	7.70	0.57	5	65.48	29.57	0.35	5	45.41	20.99	0.51	1	63.04	0.00	-	3	67.06	6.87	0.01
BM	Ever	21	78.05	12.97		37	74.47	18.62		37	39.71	17.39		21	86.18	13.56		37	86.56	12.94
IVIG	Never^c	9	84.45	7.00	0.03	17	70.85	17.81	0.50	17	37.05	21.19	0.32	8	86.14	13.94	0.80	16	81.53	11.72	0.17
IVIG	Ever^b	15	75.10	13.76		25	75.14	21.48		25	42.66	14.85		14	84.55	14.72		24	87.47	14.41
Corticosteroids	Never^c	3	81.22	8.11	0.70	6	63.51	28.86	0.19	6	38.29	28.62	0.85	2	81.52	26.13	0.71	5	82.09	11.73	0.60
Corticosteroids	Ever^b	21	78.23	13.00		36	75.05	18.11		36	40.74	15.74		20	85.49	13.53		35	85.52	13.91

Value in bold indicate significant P value
P ≤ 0.05: significant
P ≤ 0.01: highly significant
IVIG, Intravenous immunoglobulin, PLT, Platelet count, BM, Initial bone marrow examination
^aTested by ANOVA test
^bEver mean ever taking intervention within 4 weeks of questionnaires
^cNever mean never taking intervention within 4 weeks of questionnaires

ISSN: 1477-7525